Metastatic involvement of the maxillary antrum from an uncommon source.
Metastatic involvement of the jawbones is uncommon, particularly in the maxilla. Case reports of such metastases from renal cell primaries are few, making a consensus on treatment difficult to establish. We present a case of metastatic involvement of the maxilla two years following a nephrectomy for renal cell carcinoma. The case exemplifies the broad range of symptoms attributable to metastases in the maxilla and the management dilemmas.


CONCLUSIONS
The case highlights the role of practitioners in primary dental care in identifying the potential for such pathology based on clinical and radiographic features.
Rokhsareh
R
Elledge
Ross O C
RO
Elledge
Diana
D
Raskauskiene
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000556:secondary*; D059186:Chemoradiotherapy, Adjuvant; D004621:Embolization, Therapeutic; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008444:Maxillary Sinus Neoplasms / Q000556:secondary*; D009392:Nephrectomy; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010157:Palatal Neoplasms / Q000556:secondary; D010671:Phenylurea Compounds / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D000077157:Sorafenib; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D010671:Phenylurea Compounds; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib